The Met pathway: Master switch and drug target in cancer progression

Massimiliano Mazzone, Paolo M. Comoglio

Research output: Contribution to journalArticle

Abstract

It has been recognized for more than a century that most tumors tend to become more aggressive in clinical behavior over time, although this time course may be variable. This phenomenon has been termed "cancer progression," a process that appears to develop in a stepwise fashion through qualitatively different stages. Cancer progression relies on the ability of neoplastic cells to abandon their primary site of accretion, trespass tissue boundaries, and penetrate into the vasculature to colonize and repopulate distant sites. Among the various properties associated with cancer progression, the acquisition by neoplastic cells of the capacity to invade locally and to metastasize is of great clinical significance, and is still the fundamental definition of malignancy. This process represents the aberrant counterpart of a physiological morphogenetic program, known as invasive growth, occurring during embryo development and, in some instances, in adulthood for the generation and maintenance of normal organ complexity and architecture. Here we summarize some of the strategies adopted to inhibit cancer cell growth and spreading. We also review the current findings about cancer and metastasis inhibitors. As we suggest possible directions for drug development, we propose the receptor for the hepatocyte growth factor, Met, as an ideal target for tackling cancer progression.

Original languageEnglish
Pages (from-to)1611-1621
Number of pages11
JournalFASEB Journal
Volume20
Issue number10
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Proto-Oncogene Proteins c-met
Cell growth
Tumors
Switches
Tissue
drugs
neoplasms
Pharmaceutical Preparations
Neoplasms
adulthood
metastasis
Direction compound
cell growth
embryogenesis
Growth
Embryonic Development
Maintenance
Neoplasm Metastasis
neoplasm cells

Keywords

  • Crosstalk
  • HGF
  • Inhibitors
  • Invasive growth
  • Microenvironment

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

The Met pathway : Master switch and drug target in cancer progression. / Mazzone, Massimiliano; Comoglio, Paolo M.

In: FASEB Journal, Vol. 20, No. 10, 08.2006, p. 1611-1621.

Research output: Contribution to journalArticle

Mazzone, Massimiliano ; Comoglio, Paolo M. / The Met pathway : Master switch and drug target in cancer progression. In: FASEB Journal. 2006 ; Vol. 20, No. 10. pp. 1611-1621.
@article{b77e1dc2e14b4646baba35955c67d170,
title = "The Met pathway: Master switch and drug target in cancer progression",
abstract = "It has been recognized for more than a century that most tumors tend to become more aggressive in clinical behavior over time, although this time course may be variable. This phenomenon has been termed {"}cancer progression,{"} a process that appears to develop in a stepwise fashion through qualitatively different stages. Cancer progression relies on the ability of neoplastic cells to abandon their primary site of accretion, trespass tissue boundaries, and penetrate into the vasculature to colonize and repopulate distant sites. Among the various properties associated with cancer progression, the acquisition by neoplastic cells of the capacity to invade locally and to metastasize is of great clinical significance, and is still the fundamental definition of malignancy. This process represents the aberrant counterpart of a physiological morphogenetic program, known as invasive growth, occurring during embryo development and, in some instances, in adulthood for the generation and maintenance of normal organ complexity and architecture. Here we summarize some of the strategies adopted to inhibit cancer cell growth and spreading. We also review the current findings about cancer and metastasis inhibitors. As we suggest possible directions for drug development, we propose the receptor for the hepatocyte growth factor, Met, as an ideal target for tackling cancer progression.",
keywords = "Crosstalk, HGF, Inhibitors, Invasive growth, Microenvironment",
author = "Massimiliano Mazzone and Comoglio, {Paolo M.}",
year = "2006",
month = "8",
doi = "10.1096/fj.06-5947rev",
language = "English",
volume = "20",
pages = "1611--1621",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "10",

}

TY - JOUR

T1 - The Met pathway

T2 - Master switch and drug target in cancer progression

AU - Mazzone, Massimiliano

AU - Comoglio, Paolo M.

PY - 2006/8

Y1 - 2006/8

N2 - It has been recognized for more than a century that most tumors tend to become more aggressive in clinical behavior over time, although this time course may be variable. This phenomenon has been termed "cancer progression," a process that appears to develop in a stepwise fashion through qualitatively different stages. Cancer progression relies on the ability of neoplastic cells to abandon their primary site of accretion, trespass tissue boundaries, and penetrate into the vasculature to colonize and repopulate distant sites. Among the various properties associated with cancer progression, the acquisition by neoplastic cells of the capacity to invade locally and to metastasize is of great clinical significance, and is still the fundamental definition of malignancy. This process represents the aberrant counterpart of a physiological morphogenetic program, known as invasive growth, occurring during embryo development and, in some instances, in adulthood for the generation and maintenance of normal organ complexity and architecture. Here we summarize some of the strategies adopted to inhibit cancer cell growth and spreading. We also review the current findings about cancer and metastasis inhibitors. As we suggest possible directions for drug development, we propose the receptor for the hepatocyte growth factor, Met, as an ideal target for tackling cancer progression.

AB - It has been recognized for more than a century that most tumors tend to become more aggressive in clinical behavior over time, although this time course may be variable. This phenomenon has been termed "cancer progression," a process that appears to develop in a stepwise fashion through qualitatively different stages. Cancer progression relies on the ability of neoplastic cells to abandon their primary site of accretion, trespass tissue boundaries, and penetrate into the vasculature to colonize and repopulate distant sites. Among the various properties associated with cancer progression, the acquisition by neoplastic cells of the capacity to invade locally and to metastasize is of great clinical significance, and is still the fundamental definition of malignancy. This process represents the aberrant counterpart of a physiological morphogenetic program, known as invasive growth, occurring during embryo development and, in some instances, in adulthood for the generation and maintenance of normal organ complexity and architecture. Here we summarize some of the strategies adopted to inhibit cancer cell growth and spreading. We also review the current findings about cancer and metastasis inhibitors. As we suggest possible directions for drug development, we propose the receptor for the hepatocyte growth factor, Met, as an ideal target for tackling cancer progression.

KW - Crosstalk

KW - HGF

KW - Inhibitors

KW - Invasive growth

KW - Microenvironment

UR - http://www.scopus.com/inward/record.url?scp=33749367676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749367676&partnerID=8YFLogxK

U2 - 10.1096/fj.06-5947rev

DO - 10.1096/fj.06-5947rev

M3 - Article

C2 - 16873884

AN - SCOPUS:33749367676

VL - 20

SP - 1611

EP - 1621

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 10

ER -